AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds.
Abbvie Inc. (ABBV)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 2,623,100 | $549,591,912 | +36% | 0.1% | |
| 2. | 2,347,900 | $491,932,008 | +67% | 0.09% | |
| 3. | Citadel Investment Group Ken Griffin | 1,846,962 | $386,975,479 | +158% | 0.07% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,798,733 | $376,870,538 | +5% | 0.7% |
| 5. | Renaissance Technologies Jim Simons | 1,222,098 | $256,053,973 | +26% | 0.39% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing | |
| $212.34 | 17,644 | $3,746,526.96 | 11,577 | 2025-03-14 | Filing | |
| $210.53 | 6,168 | $1,298,549.04 | 388,929 | 2025-03-03 | Filing | |
| $205.11 | 92,460 | $18,964,470.60 | 395,097 | 2025-02-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 117,627 | $21,833,924 | 0.72% | |
| 2. | 45,500 | $8,445,893 | 1.74% | |
| 3. | 25,420 | $4,718,453 | 0.41% | |
| 4. | 23,060 | $4,280,305 | 1.06% | |
| 5. | 21,889 | $4,063,029 | 0.36% |
News See All
10 Undervalued S&P 500 Stocks to Buy According to Hedge Funds
On June 24, Paul Hickey, Bespoke Investment Group co-founder, joined 'Squawk Box' on CNBC to suggest that periods of widespread fear often present good buying opportunities.
AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial
AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.
Is AbbVie the Best Dividend Stock in Big Pharma Today?
The company holds the title of a Dividend King, having raised its dividend for 52 straight years.
10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing
Blue-chip stocks are great assets for investors looking for opportunities to grow their capital in the long term. Some call them steady oaks in the forest of finance.
AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C
AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.
AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement.
12 Best Healthcare Stocks to Buy Now
Healthcare companies in the US are facing policy headwinds under President Donald Trump's Administration.
10 Best Stocks to Buy For Beginners Now
On June 12, Dan Niles, Niles Investment Management founder and portfolio manager, joined CNBC's 'Squawk Box' to discuss the state of the economy and how he expects the market to catch up to reality later...
AbbVie Secures FDA Approval to Expand Mavyret’s Label
The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc.
Billionaire Hedge Funds
